Navigation Links
Neighborhood Smiles Launches a Groundbreaking Cavity Prevention Program for Their Patients
Date:3/29/2013

(PRWEB) March 29, 2013

Dental decay is the number one chronic disease affecting American youth; surpassing both obesity and asthma. For Dr.'s Kelley and Morgan those statistics are no longer daunting. They have taken the top caries research in the world and implemented a cavity prevention program developed by CariFree that is shown to decrease incidents of tooth decay by up to 74%. The system is known as CAMBRA or Caries Management by Risk Assessment. The team states: "We base all treatment plans on individual Risk Factors. Patients with high risk to decay are those on medications which dry the mouth, soda drinkers, and patients with acidic bacteria. With CariFree, we can combat these acid attacks, and sometimes reverse the effects of early decay. Now that is exciting!"

CAMBRA is rooted in a medical model of risk assessment. It requires the dental professional to assess each and every patient’s risk factors for the disease and then develop a personalized treatment plan to systematically lower their risk. The CariFree diagnostic tools leverage biofilm testing (to determine the levels of cavity-causing bacteria in the patient’s mouth) as well as a risk assessment questionnaire to determine the overall statistical probability a patient will develop new cavities over the next 12 months. Never before has such predictive information been available. Patients can then measurably lower their risk for decay by utilizing professional products and behavior modification.

Patients can expect the entire process to take a few minutes in their appointment. They will answer targeted qu
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BIOWATER Wastewater Treatment Package Plant Arrives in Residential Neighborhoods
2. Dr. Timothy Rauch of Albuquerque, New Mexico Launches a Groundbreaking Cavity Prevention Program
3. CellHealth Institute Launches with Support from Influential Investors
4. Dr. Richard Charmoy Launches Groundbreaking Cavity Prevention Program that Can Lower Tooth Decay Rates by 74%
5. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
6. BioHealth Innovation, Inc. Launches Program to Help Life Science Companies Navigate Federal Funding Application Process
7. Rockingham County Economic Development Launches New Website
8. Neogen launches rapid tests for ractopamine
9. Elsevier Launches PracticeUpdate, a Free Information Portal for Physicians
10. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
11. Darrow Wealth Management Launches New Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
(Date:2/27/2015)... 2015  Steep Hill, the industry leader in cannabis ... to open a full service medical cannabis quality assurance ... bringing advanced scientific tools and methodology to the state, ... is currently the only laboratory licensed by the New ... testing in order to meet the recently adopted regulatory ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... ... and stone how-to. , ... GA (PRWEB) September 16, 2009 - Tile Media Properties (TMP), best known for The Tile ... and tile machines. The 10 year-old Atlanta-based company receives millions of unique visitors annually and ...
... , PHILADELPHIA, Sept. 16 BioNanomatrix, Inc., a ... and personalized medicine, today announced that Dr. Charles Lee and ... Dr. Lee is a pioneer in the field of ... Medical School and the Broad Institute. Dr. Barker, the ...
... , , ... today announced that it completed the initial closing of ... will be used primarily to support the company,s ongoing ... designed to reestablish healthy vasculature following common interventions to ...
Cached Biology Technology:The Tile Doctor Launches Inaugural Product Line 2The Tile Doctor Launches Inaugural Product Line 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 2BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 4Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 2Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 3Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 4
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... each other using chemicals called neurotransmitters. One of those ... shows up in unusually high amounts in some aggressive ... School of Medicine in St. Louis. , The researchers ... lung, thyroid, and prostate cancers that spread to other ...
... analysis of ancient DNA, a team of researchers has obtained ... shared by the large predatory cats that once roamed the ... August 9 issue of Current Biology by Ross Barnett of ... Britain, the United States, Sweden, and Australia. , Toward the ...
... findings with implications for pandemic influenza, a new study reports ... influenza virus can spread from poultry to humans. The ... of Infectious Diseases, now available online. , Crossing the species ... flu virus with pandemic potential. Previous studies have focused on ...
Cached Biology News:Neurotransmitters signal aggressive cancer, offer potential for early diagnosis 2Neurotransmitters signal aggressive cancer, offer potential for early diagnosis 3DNA traces evolution of extinct sabertooths and the American cheetah-like cat 2European Commission funds EBI to do new research on synergies between bioinformatics and medical informatics 2
... The IDS Corticosterone kit is a ... of corticosterone in mouse or rat serum ... not sole, corticosteroid in rats and mice, ... amphibia, birds and reptiles. Most mammals produce ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
... for all tested applications). ... from within residues 1 - 100 of Mouse ... proprietary) (Peptide available as ... 5453 Swiss Protein ID: ...
Biology Products: